These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1455403)
21. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis. Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111 [TBL] [Abstract][Full Text] [Related]
22. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes. Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840 [TBL] [Abstract][Full Text] [Related]
23. Antithrombin III-independent effect of depolymerized holothurian glycosaminoglycan (DHG) on acute thromboembolism in mice. Nagase H; Kitazato KT; Sasaki E; Hattori M; Kitazato K; Saito H Thromb Haemost; 1997 Feb; 77(2):399-402. PubMed ID: 9157603 [TBL] [Abstract][Full Text] [Related]
24. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation]. Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289 [TBL] [Abstract][Full Text] [Related]
25. Prothrombin fragment 1 + 2, thrombin-antithrombin III-complexes and fibrinopeptide A in spontaneously clotting whole blood in vitro. Effects of heparin addition and antithrombin III deficiency. Herren T; Straub PW; Haeberli A Thromb Haemost; 1994 Jan; 71(1):49-53. PubMed ID: 8165646 [TBL] [Abstract][Full Text] [Related]
26. A survey of the clinical experience with dermatan sulfate. Gianese F; Lucchelli PE Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090 [No Abstract] [Full Text] [Related]
27. Suppression of experimental autoimmune encephalomyelitis by dermatan sulfate. Inaba Y; Ichikawa M; Koh CS; Inoue A; Itoh M; Kyogashima M; Komiyama A Cell Immunol; 1999 Dec; 198(2):96-102. PubMed ID: 10648123 [TBL] [Abstract][Full Text] [Related]
28. [Use of fragmin in program hemodialysis of patients with terminal chronic renal failure]. Kozlova TV; Shilo VIu; Denisov AIu Klin Med (Mosk); 2005; 83(9):45-9. PubMed ID: 16279040 [TBL] [Abstract][Full Text] [Related]
29. A dose ranging study to evaluate dermatan sulphate in preventing deep vein thrombosis following total hip arthroplasty. Cohen AT; Phillips MJ; Edmondson RA; Skinner JA; Das SK; Cooper DJ; Thomas EM; Melissari E; Kakkar VV Thromb Haemost; 1994 Dec; 72(6):793-8. PubMed ID: 7740443 [TBL] [Abstract][Full Text] [Related]
30. The anticoagulant effect of heparinoid Org 10172 during haemodialysis: an objective assessment. Ireland H; Lane DA; Flynn A; Anastassiades E; Curtis JR Thromb Haemost; 1986 Apr; 55(2):271-5. PubMed ID: 3715791 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis--evidence for an anticoagulant-independent mechanism. Barbanti M; Calanni F; Milani MR; Marchi E; Semeraro N; Colucci M Thromb Haemost; 1993 Feb; 69(2):147-51. PubMed ID: 8456427 [TBL] [Abstract][Full Text] [Related]
32. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins. Bendayan P; Boccalon H; Dupouy D; Boneu B Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383 [TBL] [Abstract][Full Text] [Related]
33. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Ljungberg B; Blombäck M; Johnsson H; Lins LE Clin Nephrol; 1987 Jan; 27(1):31-5. PubMed ID: 3815906 [TBL] [Abstract][Full Text] [Related]
34. Coagulation inhibition capacities of low-molecular mass and unfractionated heparin, as determined by thrombin generation. Elgue G; Sanchez J; Egberg N; Olsson P Thromb Res; 1994 Sep; 75(5):539-49. PubMed ID: 7992254 [TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics and pharmacodynamics of dermatan sulphate MF701 during haemodialysis for chronic renal failure. Gianese F; Nurmohamed MT; Imbimbo BP; Büller HR; Berckmans RJ; Ten Cate JW Br J Clin Pharmacol; 1993 Mar; 35(3):335-9. PubMed ID: 8471416 [TBL] [Abstract][Full Text] [Related]
36. Measurement of fibrinopeptide A in the evaluation of heparin activity and fibrin formation during hemodialysis. Wilhelmsson S; Asaba H; Gunnarsson B; Kudryk B; Robinson D; Bergström J Clin Nephrol; 1981 May; 15(5):252-8. PubMed ID: 7249422 [TBL] [Abstract][Full Text] [Related]
37. Fibrin moderates the catalytic action of heparin but not that of dermatan sulfate on thrombin inhibition in human plasma. Okwusidi JI; Anvari N; Kulczycky M; Blajchman MA; Buchanan MR; Ofosu FA J Lab Clin Med; 1991 May; 117(5):359-64. PubMed ID: 2019790 [TBL] [Abstract][Full Text] [Related]
38. Pharmacological actions of sulodexide. Ofosu FA Semin Thromb Hemost; 1998; 24(2):127-38. PubMed ID: 9579633 [TBL] [Abstract][Full Text] [Related]
39. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Anastassiades E; Lane DA; Ireland H; Flynn A; Curtis JR Clin Nephrol; 1989 Dec; 32(6):290-6. PubMed ID: 2558829 [TBL] [Abstract][Full Text] [Related]
40. Dermatan sulphate in haemodialysis. Lane DA; Ryan K; Ireland H; Curtis JR; Nurmohamed MT; Krediet RT; Roggekamp MC; Stevens P; ten Cate JW Lancet; 1992 Feb; 339(8789):334-5. PubMed ID: 1346414 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]